Section Arrow
CDTX.NASDAQ
- Cidara Therapeutics
Quotes are at least 15-min delayed:2025/07/21 07:21 EDT
Pre Market
Last
 59.96
0 (0.00%)
Bid
59.9
Ask
60.7
High 60.7 
Low 59.96 
Volume
Regular Hours
Last
 59.96
+3.81 (+6.79%)
Day High 
61.6 
Prev. Close
56.15 
1-M High
56.8288 
Volume 
1.11M 
Bid
59.9
Ask
60.7
Day Low
54.5183 
Open
56.47 
1-M Low
20.16 
Market Cap 
1.24B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 51.51 
20-SMA 47.08 
50-SMA 32.62 
52-W High 61.6 
52-W Low 10.14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-26.13/-7.98
Enterprise Value
1.24B
Balance Sheet
Book Value Per Share
6.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.28M
Operating Revenue Per Share
2.56
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.05 -0.23 -10.09%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 12.65 -1.425 -10.12%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0482 +0.0005 +1.05%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.215 +0.375 +6.42%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.29 +0.37 +6.25%
Quotes are at least 15-min delayed:2025/07/21 07:21 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.